fashion -WSS

fashion

author：knowledge 2025-09-27 19:38:02 - browse：312

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Reporting on presidential health from Reagan to Trump and Biden

WSS

Weight loss drugs aren’t covered by Obamacare. That may change

FDA warns medical device makers about rise in fabricated data

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Will the market for weight loss drugs really reach $100 billion?

Diagnostic tests are hitting their mathematical limits

What to do when lifesaving products contribute to climate change

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Weight loss drugs aren’t covered by Obamacare. That may change

Drug repurposing or repositioning? The language matters

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Hollywood unions extend contract negotiations for actors

How to pay for weight loss drugs and save Medicare

Bright Health sells Medicare Advantage business to Molina

Ukraine seeks to reclaim its role as a hub for clinical trials

Wildfire smoke exposes gaps in outdoor worker protections

Opioid cravings were reduced by anti

focus

BIO selects John Crowley as new CEO

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

What don’t we know about an Alzheimer’s drug side effect?

Researchers tackle phage therapy hurdles for wider adoption

Flagship Pioneering startup Sonata Therapeutics lays off 21

explore

explore

focus

hotspot